Novo Nordisk : Q1 2020 momentum will not last
>Q1 2020 marked by stockpiling effect - Following management’s conference call, we confirm that Q1 was marked by a significant stockpiling of the group's chronic-use treatments (stockpiling in particular at the patient level) in anticipation of lockdown measures around the world. However, COVID-19 will have a more negative impact on Novo between now and Q3 with a reversal of the stockpiling effect and the economic impact of the crisis in the US.Semaglutid...Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.